YingbaiRui Announces Successful First-in-Human Dosing in Phase I Trial of IBR733, the World’s First Bispecific CD33/CLL1 Antibody-Conjugated NK Cell Therapy for Acute Myeloid Leukemia

Apr 19, 2024 11:32 CST Updated 11:32

iMBioRay

CAR-NK Cell Therapy Drug Developer

2024Year4Month17Date, Imbioray (Hangzhou) Biopharmaceutical Co., Ltd.IBR733Cell Injection for the Treatment of Acute Myeloid Leukemia (AML) ofIThe first subject of the Phase I clinical trial was successfully dosed at the First Affiliated Hospital of Soochow University. The infusion process went smoothly, and the patient's vital signs remained stable.

IBR733Cell Injection Receives World's First Approval for Acute Myeloid Leukemia IndicationINDClinical ResearchCD33AndCLL1Dual-Target Antibody ConjugationNKCell product. It adopts imbioray's unique specific antibody targeting tumor antigens.CD33/CLL1Through the linker andNKCells undergo chemical covalent conjugation, which is an off-the-shelf, universal type that is non-viral vector and non-genetically modified.NKCell products with extremely high safety and powerful tumor cell killing ability.IBR733Cell injection has previously been involved in several investigator-initiated clinical trials (IIT), and achieved excellent results in terms of safety and efficacy.

The Phase I clinical trial of IBR733 cell injection is being conducted at renowned clinical research centers in China, including the First Affiliated Hospital of Soochow University, Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, the First Affiliated Hospital of Zhejiang University School of Medicine, West China Hospital of Sichuan University, and Zhongda Hospital affiliated with Southeast University. Imbioray will closely collaborate with each research center to actively advance the trial.IBR733Clinical Development,Is expected to bring new treatment options and survival hope to more patients with acute myeloid leukemia.

About Imbioray

Imbioray is a clinical-stage and venture-backed innovative biopharmaceutical company, primarily focused on cutting-edge global advancements in tumor immunotherapy, as well as immunological diseases, chronic conditions, andCNSDevelopment of innovative immunotherapy drugs for such diseases. Dr. Zhenwei Miao, founder of Imbioray2016Returned to China to start a business in the year, establishing imbioray based onNKThe direction of developing off-the-shelf universal cell drugs. Imbioray has internationally original4Large core technology platforms accelerate the company's innovation at the source, with internationally leading large-scale closed-system in vitro cultivation.NKAdvanced Cell Technology. Based on proprietary antibody conjugationNKCell Platform Technology DevelopmentIBR854、IBR733、IBR822And many other off-the-shelf cell therapy products. Currently, the world's first innovation for advanced solid tumorsIBR854Cell Injection and the World's First Targeting Acute Myeloid LeukemiaIBR733Cell injection has enteredIPhase of clinical trial.IBR822Is Imbioray's third antibody-NKCell Coupling Drugs, Currently IND is inCDE Review Phase。

E.N.D

Previous article recommendation:

Hengrui Medicine Subsidiary's First Gene Therapy Product Approved for Clinical Trials

Shenzhen Cell Valley Successfully Completes Nearly 100 Million Yuan in Angel+Pre-A Round of Capital Increase and Share Expansion

Another CAR-T Commercial Production Base in China Breaks Ground

Heavyweight! "Beijing Municipality's Several Measures to Support the High-Quality Development of Innovative Pharmaceuticals (2024)" Released

Bi Jingquan: Understanding Innovative Drugs from the Perspective of Innovation and Clinical Value

Yi Zun Bio Completes Nearly 100 Million Yuan A+ Round Financing

Zhuàn Code Biotech Completes Tens of Millions of Yuan in Seed Funding, Advances Development of Original Ultra-Compact and Efficient Gene Editor

Shanghai Pharmaceutical Biotech's CAR-iNKT and AXL-CAR T Cell Therapies Debut at the 2024 AACR Conference

Global Renowned Investment Bank: It's Time to Invest in Biotechnology

New Gene Therapy Vector Unveiled! Promising Effective and Safe Repeated Dosing

Sanofi Shuts Down NK Cell Therapy Company Acquired for Hundreds of Millions of Dollars

Shanghai Ninth People's Hospital Successfully Develops the World's First Gene Therapy for Congenital Deafness Based on Gene Editing Technology

Xiangya Hospital Children's Medical Center Launches Clinical Trial of AAV Gene Therapy Drug NKG001 for Spinal Muscular Atrophy

Cell Therapy Enters the Era of Solid Tumors

The U.S. "Biosecurity Act" May Include MoreChinese CXO Companies

World's First: Patient Receives Genetically Edited Pig Kidney Transplant and Is Discharged Successfully

Legend Biotech's CAR-T Drug CARVYKTI® Approved for Second-Line Indication in the U.S.

Top Ten Trends in the 2024 Synthetic Biology Industry Track: Cell and Gene Therapy, Gene Editing, Next-Generation Sequencing, etc.

Imbioray's CAR-T Product Ixazomib Injection Receives FDA Approval for New Autoimmune Indication

First Case in China! 12-Year-Old Girl with Lupus Successfully Receives CAR-T Treatment and Has Been Discharged Smoothly

U.S. Congress Hawks on China Seek to Add BGI, Novozymes to Pentagon Warning List

US Intelligence Officials: WuXi AppTec Transfers US Client Intellectual Property to China

Investment of 2 Billion Yuan, Focusing on Cell Immunotherapy and Other Directions: Lingang Branch of Pudong Hospital Begins Construction

Totally Blind Patients Regain Sight: Jian Da Jiu Zhou Makes Significant Breakthrough in Optogenetic Gene Therapy

Construction Begins on Imbioray's Global R&D Headquarters in Zhangjiang, Covering Approximately 90,000 Square Meters

Positive Phase 2b Clinical Results for Optogenetics-Based AAV Gene Therapy; Plan to Submit Marketing Application

Disclaimer: The content is sourced from the official imbioray. This article aims to share knowledge, and all content is for reference only and does not constitute any advice.